- Home
- JRS vs CNTX Comparison
JRS vs CNTX Comparison
Compare JRS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRS | CNTX |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.9M | 209.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JRS | CNTX |
|---|---|---|
| Price | $8.18 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 71.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | ★ 69.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.56 | $0.49 |
| 52 Week High | $8.92 | $2.85 |
Technical Indicators
Market Signals| Indicator | JRS | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.68 | 58.72 |
| Support Level | $7.55 | $2.06 |
| Resistance Level | $8.38 | $2.58 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 90.38 | 46.67 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.